SCHEMBL15907820

SCHEMBL15907820

CC(C)(O)c1cccc2onc(N)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.47
FLT3 P36888 10/20 0.47
KIT P10721 10/20 0.47
AURKB Q96GD4 7/20 0.47
MET P08581 3/20 0.47
MAP4K4 O95819 2/20 0.47
PDGFRB P09619 2/20 0.47
PIM1 P11309 2/20 0.47
FGFR1 P11362 2/20 0.47
PDGFRA P16234 2/20 0.47
PRKACA P17612 2/20 0.47
LTK P29376 2/20 0.47
GRK5 P34947 2/20 0.47
CDK8 P49336 2/20 0.47
CDK7 P50613 2/20 0.47
CDK9 P50750 2/20 0.47
LIMK1 P53667 2/20 0.47
MAP2K1 Q02750 2/20 0.47
ACVR1 Q04771 2/20 0.47
MST1R Q04912 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17030757 0.86 KDR (0.50) KDRFLT3KITAURKBMET
SCHEMBL20963390 0.83 KDR (0.47) KDRFLT3KITAURKBMET
SCHEMBL17278412 0.81 KCNA5 (0.39) KDRFLT3KITAURKBMET
SCHEMBL24402745 0.81 KCNA5 (0.42) KDRFLT3KITAURKBMET
SCHEMBL21609072 0.79 KDR (0.50) KDRFLT3KITAURKBMET
SCHEMBL15907821 0.73 KDR (0.37) KDRFLT3KITAURKBMET
SCHEMBL16646799 0.73 KDR (0.57) KDRFLT3KITAURKBMET
SCHEMBL2882058 0.73 KDR (0.57) KDRFLT3KITAURKBMET
SCHEMBL2445430 0.72 KDR (0.58) KDRFLT3KITAURKBMET
Hydrochloric Acid SCHEMBL5103456 0.71 KDR (0.56) KDRFLT3KITAURKBMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771664-B2 Toxic aldehyde related diseases and treatment ALDEYRA THERAPEUTICS, INC. (US) 2023-10-03 US disclosed
US-11771664-B2 Toxic aldehyde related diseases and treatment ALDEYRA THERAPEUTICS, INC. (US) 2023-10-03 US disclosed
US-20230293527-A1 TREATMENT OF INFLAMMATORY DISORDERS ALDEYRA THERAPEUTICS, INC. 2023-09-21 US disclosed
US-20230293527-A1 TREATMENT OF INFLAMMATORY DISORDERS ALDEYRA THERAPEUTICS, INC. 2023-09-21 US disclosed
US-20230248727-A1 TREATMENT OF INFLAMMATORY DISORDERS ALDEYRA THERAPEUTICS, INC. 2023-08-10 US disclosed
US-20230248727-A1 TREATMENT OF INFLAMMATORY DISORDERS ALDEYRA THERAPEUTICS, INC. 2023-08-10 US disclosed
US-11701331-B2 Toxic aldehyde related diseases and treatment ALDEYRA THERAPEUTICS, INC. (US) 2023-07-18 US disclosed
US-11701331-B2 Toxic aldehyde related diseases and treatment ALDEYRA THERAPEUTICS, INC. (US) 2023-07-18 US disclosed
US-11583529-B2 Treatment of inflammatory disorders ALDEYRA THERAPEUTICS, INC. (US) 2023-02-21 US disclosed
US-20220202745-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDEYRA THERAPEUTICS, INC. 2022-06-30 US disclosed
US-20170239196-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) 2017-08-24 US disclosed
US-9687481-B2 Toxic aldehyde related diseases and treatment ALDEYRA THERAPEUTICS, INC. (US) 2017-06-27 US disclosed
US-9687481-B2 Toxic aldehyde related diseases and treatment ALDEYRA THERAPEUTICS, INC. (US) 2017-06-27 US disclosed
WO-2017035082-A1 ALDEHYDE CONJUGATES AND USES THEREOF ALDEYRA THERAPEUTICS, INC. (US) 2017-03-02 WO disclosed
US-20150344447-A1 NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION ALDEXA THERAPEUTICS, INC. 2015-12-03 US disclosed
US-20150344447-A1 NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION ALDEXA THERAPEUTICS, INC. 2015-12-03 US disclosed
US-20150335632-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) 2015-11-26 US disclosed
US-20150335632-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) 2015-11-26 US disclosed
WO-2014116836-A2 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDEXA THERAPEUTICS, INC. (US) 2014-07-31 WO disclosed
WO-2014116593-A1 NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION ALDEXA THERAPEUTICS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293527-A1 TREATMENT OF INFLAMMATORY DISORDERS TNF, NFKBIA, LTB4R2 KDR 4522/4885FLT3 3169/4885KIT 3044/4885
US-11583529-B2 Treatment of inflammatory disorders TNF, NFKBIA, LTB4R2 KDR 4522/4885FLT3 3169/4885KIT 3044/4885
US-20170239196-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDH1A2, ALDH2, ALDH1A1 KDR 1942/4885FLT3 4802/4885KIT 2641/4885
US-20150344447-A1 NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION PDE6C, PDE6D, PDE6A KDR 336/4885FLT3 3462/4885KIT 2551/4885
US-11771664-B2 Toxic aldehyde related diseases and treatment ALDH1A2, ALDH2, ALDH1A1 KDR 1942/4885FLT3 4802/4885KIT 2641/4885
US-11701331-B2 Toxic aldehyde related diseases and treatment ALDH1A2, ALDH2, ALDH1A1 KDR 1942/4885FLT3 4802/4885KIT 2641/4885
US-20230248727-A1 TREATMENT OF INFLAMMATORY DISORDERS TNF, NFKBIA, LTB4R2 KDR 4522/4885FLT3 3169/4885KIT 3044/4885
US-20220202745-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDH1A2, ALDH2, ALDH1A1 KDR 1942/4885FLT3 4802/4885KIT 2641/4885
US-20150335632-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDH1A2, ALDH2, ALDH1A1 KDR 1942/4885FLT3 4802/4885KIT 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.